Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Kaiyang Ding
Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study
Abstract Ifupinostat (BEBT-908) is a novel dual-targeted inhibitor of histone deacetylase (HDACs) and phosphatidylinositol 3-kinase alpha (PI3Kα). We evaluated the efficacy and safety of ifupinostat monotherapy in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. Eligible participants received intravenous ifupinostat at 22.5 mg/m² on days 1, 3, 5, 8, 10, and 12 of a 21-day cycle.
Safety and efficacy of birelentinib, a novel LYN/BTK dual inhibitor, in relapsed/refractory diffuse large B-cell lymphoma: a phase 2 study (TAI-SHAN9)
Abstract In this phase 2 TAI-SHAN9 study, we evaluated the safety and efficacy of birelentinib, a first-in-class oral dual inhibitor of LYN and BTK, in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). A total of 58 patients were enrolled and received birelentinib at doses ranging from 25 to 75 mg once daily (QD).
Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial
Abstract While involved-site radiotherapy (ISRT) is the standard first-line treatment in localized non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the cumulative risk of distant relapse poses a persistent clinical challenge. We conducted a prospective phase II trial evaluating rituximab with 24 Gy ISRT, aiming to reduce distant relapse and enhance long-term survival. By October 2025, 60 patients with early-stage non-gastric MALT lymphoma were enrolled.
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial
|
Abstract Orelabrutinib is a potent, irreversible, and highly-selective BTK inhibitor that has been approved for the treatment of relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). This randomized, phase 3 study (ClinicalTrials.gov identifier: NCT04578613) compared orelabrutinib with chemoimmunotherapy in patients with treatment-naïve CLL/SLL.
By Keshu Zhou, Wei Xu, Guohui Cui, Shuhua Yi, Jie Jin, Zunmin Zhu, Aili He, Jianqing Mi, Zhongjun Xia, Xiaobing Huang, Xin Zhou, Wenzheng Yu, Jingming Guo, Qingshu Zeng, Shihua Huang, Yuerong Shuang, Hongling Peng, Lihua Qiu, Bing Xu, Fuling Zhou, Yafei Wang, Lihong Liu, Ying Li, Wei Yang, Jian Gu, Guifang Ouyang, Luoming Hua, Jin Zhang, Qing Xiao, Shunqing Wang, Qingyuan Zhang, Jing J. Liu, Kaiyang Ding, Liansheng Zhang, Yun Zeng, Zhenyu Li, Qin Wen, Kaibo Gao, Haiping Yang, Yirong Jiang, Yijian Chen, Zengjun Li, Xinran Tang, Lugui Qiu, Jianyong Li, Jinhai Ren, Weige Wang, Renbin Zhao
|
Nature
Verified
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
Abstract Patients with peripheral T cell lymphoma (PTCL) who achieved tumor response with first-line standard therapy were at high risk of disease relapse. We explored golidocitinib (150 mg once daily) as maintenance therapy for this group of patients (JACKPOT26, NCT06511869). This study included two cohorts: patients achieving a complete response (Cohort 1 (CR), N = 30) and a partial response (Cohort 2 (PR), N = 18) during induction stage.
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma | BMC Cancer | Full Text
This ongoing, multicenter, noninterventional, observational registry study (Chinese Clinical Trial Registry Identifier: ChiCTR2200055491; registered January 10, 2022) is enrolling Chinese patients who have been diagnosed with symptomatic NDMM or RRMM. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, Good Clinical Practices, and abided by all applicable regulatory requirements.
Deep Learning Empowered Parallelized Metasurface Computed Tomography Snapshot Spectral Imaging
Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adma202419383-sup-0001-SuppMat.docx2.1 MB Supporting Information References 1, , , Cytometry, Part A 2006, 69A, 735. 2, , , , , , , , , Optica 2019, 6, 702. 3, , , , , , , , , Eur. Urol. 2020, 77, 251. 4, J. Opt. 2020, 22, 103001. 5, , , , , , , SPIE 2019, 11155, 1115502. 6, , , , , Appl. Opt. 2020, 59, 5226. 7, , , , , , Combust. Flame 2021, 233, 111568. 8, , , , , , Appl. Opt. 2019, 58, 826.
A Multi-Source-Data-Assisted AUV for Path Cruising: An Energy-Efficient DDPG Approach
1. Introduction The marine industry has rapidly developed thanks to the increasing attention being paid to the ocean worldwide. The intricacy and unpredictability of the marine environment present substantial challenges to the effective exploitation and utilization of ocean resources.
Improved Artificial Potential Field Algorithm Assisted by Multisource Data for AUV Path Planning
Open AccessArticle by Tianyu Xing †, Xiaohao Wang †, Kaiyang Ding , Kai Ni and Qian Zhou * Division of Advanced Manufacturing, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China * Author to whom correspondence should be addressed. † These authors contributed equally to this work.
Three-dimensional morphology measurement of underwater objects based on the photoacoustic effect
Kaiyang Ding, Xingming Wang, Kai Hu, Lidai Wang, Guanhao Wu, Kai Ni, and Qian Zhou Author Information Author Affiliations Kaiyang Ding,1,† Xingming Wang,1,† Kai Hu,1 Lidai Wang,2 Guanhao Wu,3 Kai Ni,1,4 and Qian Zhou1,5 1Division of Advanced Manufacturing, Tsinghua Shenzhen International Graduate School, Tsinghua University, Tsinghua Campus, University Townof Shenzhen, 518055, China 2City University of Hong Kong, Department of Biomedical Engineering, Kowloon, Hong Kong, China 3State Key...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Kaiyang
Contact Kaiyang, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack